|  |  |  |  |
| --- | --- | --- | --- |
| **BASEC-Nr.** | **Atopische Dermatitis** | **Kontaktdaten** | **Status** |
| 2021-01911 | AD-VISE | Real world utilization of upadacitinib in adult and adolescent patients livingwith moderate to severe atopic dermatitis (AD-VISE) | Prof. Dr. Dr. Antonio CozzioAntonio.cozzio@kssg.ch Jana SzaboJana.szabo@kssg.ch  | **Einschluss möglich** |
| Noch nicht bekannt | LeveL-Up | A Phase 3b/4 Randomized, Open-label, Efficacy Assessor Blinded Study, Comparing theSafety and Assessor Blinded Efficacy of Upadacitinib to Dupilumab in Subjects with Moderate to SevereAtopic Dermatitis (Level-Up) | Dr. Ieva SauliteIeva.saulite@kssg.ch Alisha SyedAlisha.syed@kssg.ch  | **Einschluss ab Frühling 2023 möglich** |
| Noch nicht bekannt | ROCKET SHUTTLE | A Phase 3, Randomized, 24-week,Placebo-controlled, Double-blind Study toAssess the Efficacy, Safety, and Tolerabilityof Rocatinlimab (AMG 451) in CombinationWith Topical Corticosteroids and/or TopicalCalcineurin Inhibitors in Adult Subjects WithModerate-to-severe Atopic Dermatitis (AD)(ROCKET-SHUTTLE) | Prof. Dr. Dr. Antonio CozzioAntonio.cozzio@kssg.ch Jana SzaboJana.szabo@kssg.ch  | **Einschluss ab Frühling/ Sommer 2023 möglich** |

|  |  |  |  |
| --- | --- | --- | --- |
| **BASEC-Nr.** | **Basalzellkarzinom / kutanes Plattenepithelkarzinom** | **Kontaktdaten** | **Status** |
| 2018-01154 | DUNCAN /PH-L19IL2TNFNMSC | A phase II study of intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patients with presence of injectable lesions. | Prof. Dr. Lukas FlatzLukas.flatz@kssg.ch Alisha SyedAlisha.syed@kssg.ch  | **Einschluss möglich** |
| 2022-00155 | CEMISKIN / OBS16381 | Two cohort registry study for patients with advanced CSCC treated with Cemiplimab or otherapproaches | Dr. Nikolaus WagnerNikolaus.wagner@kssg.ch Tanja Zeller Tanja.zeller@kssg.ch | **Einschluss möglich** |

|  |  |  |  |
| --- | --- | --- | --- |
| **BASEC-Nr.** | **Kutaner Lupus** | **Kontaktdaten** | **Status** |
| 2022-01866 | AMETHYST / 203LE301 | A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized,Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate theEfficacy and Safety of BIIB059 in Participants with Active SubacuteCutaneous Lupus Erythematosus and/or Chronic Cutaneous LupusErythematosus with or without Systemic Manifestations and Refractoryand/or Intolerant to Antimalarial Therapy (AMETHYST) | Prof. Dr. Dr. Antonio CozzioAntonio.cozzio@kssg.ch Jana SzaboJana.szabo@kssg.ch  | **Einschluss ab Frühling 2023 möglich** |

|  |  |  |  |
| --- | --- | --- | --- |
| **BASEC-Nr.** | **Melanom** | **Kontaktdaten** | **Status** |
| 2022-00440 | NEO-DREAM / PH-L19IL2TNF-01/18

|  |
| --- |
|  |

 |

|  |
| --- |
| An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Patients  |

 | Dr. Nikolaus WagnerNikolaus.wagner@kssg.ch Alisha SyedAlisha.syed@kssg.ch  | **Einschluss möglich** |
| 2020-00339 | NIS BERING | Encorafenib plus binimetinib in patients withlocally advanced, unresectable or metastatic BRAFV600-mutated melanoma:a multi-centric, national, prospective, longitudinal,non-interventional study in Switzerland – BERINGMELANOMA  | Dr. Nikolaus WagnerNikolaus.wagner@kssg.ch Tanja Zeller Tanja.zeller@kssg.ch | **Einschluss möglich** |
| 2018-01154 | Keynote 716 / MK3475-716 | Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-Blind Phase 3 Study | Prof. Dr. Lukas FlatzLukas.flatz@kssg.ch Jana SzaboJana.szabo@kssg.ch  | **Kein** Einschluss mehr möglich |

|  |  |  |  |
| --- | --- | --- | --- |
| **BASEC-Nr.** | **Mycosis Fungoides (MF) / Sézary Syndrome (SS)** | **Kontaktdaten** | **Status** |
| 016-01795 | RESMAIN study/ 4SC-201-6-2015 | A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy | Prof. Dr. Dr. Antonio CozzioAntonio.cozzio@kssg.ch Alisha SyedAlisha.syed@kssg.ch  | **Kein** Einschluss mehr möglich |

|  |  |  |  |
| --- | --- | --- | --- |
| **BASEC-Nr.** | **Psoriasis** | **Kontaktdaten** | **Status** |
| 2021-01705 | POSITIVE / M-14745-47 | A multicentre, prospective observational RWE study to assess Patient reported wellbeing using tildrakizumab in a live setting – POSITIVE Study | Dr. Ieva SauliteIeva.saulite@kssg.ch Jana SzaboJana.szabo@kssg.ch  | **Kein** Einschluss mehr möglich |
| 2016-01782 | SDNTT | **Swiss Dermatology Network for Targeted Therapies (SDNTT) Objective**Long-Term Benefits and Safety of Systemic Psoriasis Therapy:Swiss Registry on the Treatment of Psoriasis with Biologics and Systemic Therapeutics based on PsoBest German Registry and in operational cooperation with CVderm in Hamburg | Prof. Dr. Dr. Antonio CozzioAntonio.cozzio@kssg.ch Jana SzaboJana.szabo@kssg.ch  | **Einschluss möglich** |

Alle Informationen zur Klinischen Forschung der Klinik für Dermatologie, Venerologie und Allergologie finden Sie unter: <https://www.kssg.ch/dermatologie/klinische-forschung>